Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5782-5797

  Jayachandran, Aparna ^a,b   Anaka, Matthew ^a,b   Prithviraj, Prashanth ^a,b   Hudson, Christopher ^a   McKeown, Sonja J ^b   Lo, Pu Han ^a   Vella, Laura J ^a,b   Goding, Colin R ^c   Cebon, Jonathan ^a,b   Behren, Andreas ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Chick embryo; Drug resistance; Epithelial to mesenchymal transition; Invasion; Melanoma; Thrombospondin 1

Indexed keywords

B RAF KINASE; MELAN A; MESSENGER RNA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOPHENOL MONOOXYGENASE; NERVE CELL ADHESION MOLECULE; NEUTRALIZING ANTIBODY; SMALL INTERFERING RNA; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VEMURAFENIB;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL DEDIFFERENTIATION; CELL INVASION; CELL JUNCTION; CELL MOTILITY; CELL POLARITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; METASTATIC MELANOMA; MOUSE; NEURAL TUBE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR INVASION; UPREGULATION; ANIMAL; BIOSYNTHESIS; CELL DIFFERENTIATION; GENETICS; METABOLISM; PATHOLOGY; SECRETION (PROCESS); TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; HETEROGRAFTS; HUMANS; MELANOMA; MICE; PHENOTYPE; THROMBOSPONDIN 1;

EID: 84906235491     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2164     Document Type: Article

References (67)

1. Miller AJ and Mihm MC Jr. Melanoma. N Engl J Med. 2006; 355(1):51-65.
2. Lito P, Rosen N and Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013; 19(11):1401-1409.
3. Villanueva J, Vultur A and Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 2011; 71(23):7137-7140.
4. Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J, Hutchinson P, Tse G, Lachuer J, Puisieux A, Pringle JH, Ansieau S and Tulchinsky E. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell. 2013; 24(4):466-480.
5. Kim JE, Leung E, Baguley BC and Finlay GJ. Heteroge-neity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines. Front Genet. 2013; 4:97.
6. Wehbe M, Soudja SM, Mas A, Chasson L, Guinamard R, de Tenbossche CP, Verdeil G, Van den Eynde B and Schmitt-Verhulst AM. Epithelial-mesenchymal-transition-like and TGF-beta pathways associated with autochthonous inflammatory melanoma development in mice. PLoS One. 2012; 7(11):e49419.
7. Duband JL. Diversity in the molecular and cellular strategies of epithelium-to-mesenchyme transitions: Insights from the neural crest. Cell Adh Migr. 2010; 4(3):458-482.
8. Scheel C and Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol. 2012; 22(5-6):396-403.
9. Bedi U, Mishra VK, Wasilewski D, Scheel C and Johnsen SA. Epigenetic plasticity: a central regulator of to-mesenchymal transition in cancer. Oncotarget. 2014; 5(8):2016-2029.
10. Kalluri R and Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-1428.
11. Polyak K and Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9(4):265-273.
12. Singh A and Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29(34):4741-4751.
13. Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Korbel C, Laschke MW, Gimotty PA, Philipp SE, Krause E, Patzold S, Villanueva J, Krepler C, Fukunaga-Kalabis M and Hoth M. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell. 2013; 23(6): 811-825.
14. Carlson CB, Lawler J and Mosher DF. Structures of thrombospondins. Cell Mol Life Sci. 2008; 65(5):672-686.
15. Miyata Y and Sakai H. Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects. Int J Mol Sci. 2013; 14(6):12249-12272.
16. Kudo-Saito C, Shirako H, Takeuchi T and Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009; 15(3):195-206.
17. Tsuchida R, Osawa T, Wang F, Nishii R, Das B, Tsuchida S, Muramatsu M, Takahashi T, Inoue T, Wada Y, Minami T, Yuasa Y and Shibuya M. BMP4/Thrombospondin-1 loop paracrinically inhibits tumor angiogenesis and suppresses the growth of solid tumors. Oncogene. 2013.
18. Bige N, Shweke N, Benhassine S, Jouanneau C, Vandermeersch S, Dussaule JC, Chatziantoniou C, Ronco P and Boffa JJ. Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction. Kidney Int. 2012; 81(12):1226-1238.
19. Massague J. TGF-beta signalling in context. Nat Rev Mol Cell Biol. 2012; 13(10):616-630.
20. Mikesh LM, Kumar M, Erdag G, Hogan KT, Molhoek KR, Mayo MW and Slingluff CL Jr. Evaluation of molecular markers of mesenchymal phenotype in melanoma. Melanoma Res. 2010; 20(6):485-495.
21. Liu F, Gomez Garcia AM and Meyskens FL Jr. NADPH oxidase 1 overexpression enhances invasion via matrix metalloproteinase-2 and epithelial-mesenchymal transition in melanoma cells. J Invest Dermatol. 2012; 132(8):2033-2041.
22. Behren A, Anaka M, Lo PH, Vella LJ, Davis ID, Catimel J, Cardwell T, Gedye C, Hudson C, Stan R and Cebon J. The Ludwig institute for cancer research Melbourne melanoma cell line panel. Pigment cell & melanoma research. 2013; 26(4):597-600.
23. Verrecchia F, Chu ML and Mauviel A. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. The Journal of biological chemistry. 2001; 276(20):17058-17062.
24. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, Fehm T, Solomayer E, Riess O, Wallwiener D, Kurek R and Neubauer HJ. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer research. 2006; 66(10):5278-5286.
25. Wu Y, Siadaty MS, Berens ME, Hampton GM and Theodorescu D. Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene. 2008; 27(52):6679-6689.
26. Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D, de Bono B, Garapati P, Hemish J, Hermjakob H, Jassal B, Kanapin A, Lewis S, Mahajan S, May B, Schmidt E and Vastrik I. Reactome knowledgebase of human biological pathways and processes. Nucleic acids research. 2009; 37((Database issue)):D619-622.
27. Anastassiou D, Rumjantseva V, Cheng W, Huang J, Canoll PD, Yamashiro DJ and Kandel JJ. Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo. BMC cancer. 2011; 11:529.
28. Gotzmann J, Fischer AN, Zojer M, Mikula M, Proell V, Huber H, Jechlinger M, Waerner T, Weith A, Beug H and Mikulits W. A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene. 2006; 25(22):3170-3185.
29. Jechlinger M, Grunert S, Tamir IH, Janda E, Ludemann S, Waerner T, Seither P, Weith A, Beug H and Kraut N. Expression profiling of epithelial plasticity in tumor progression. Oncogene. 2003; 22(46):7155-7169.
30. Moustakas A and Heldin P. TGF-beta and matrix-regulated epithelial to mesenchymal transition. Biochimica et biophysica acta. 2014.
31. Perrot CY, Gilbert C, Marsaud V, Postigo A, Javelaud D and Mauviel A. GLI2 cooperates with ZEB1 for transcriptional repression of CDH1 expression in human melanoma cells. Pigment cell & melanoma research. 2013; 26(6):861-873.
32. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signalling. 2013; 6(269):pl1
33. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discovery. 2013; 2(5):401-405
34. Salti GI, Manougian T, Farolan M, Shilkaitis A, Majumdar D and Das Gupta TK. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer research. 2000; 60(18):5012-5016.
35. Goding CR. Commentary. A picture of Mitf in melanoma immortality. Oncogene. 2011; 30(20):2304-2306.
36. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, Lee F, Shaw P and Clark E. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer research. 2007; 67(5):2226-2238.
37. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, Nagle R and Bearss D. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene. 2007; 26(27):3909-3919.
38. Bailey CM, Morrison JA and Kulesa PM. Melanoma revives an embryonic migration program to promote plasticity and invasion. Pigment cell & melanoma research. 2012; 25(5):573-583.
39. Busch C, Krochmann J and Drews U. The chick embryo as an experimental system for melanoma cell invasion. PLoS One. 2013; 8(1):e53970.
40. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A and Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468(7326):973-977.
41. Hoek KS, Eichhoff OM, Schlegel NC, Dobbeling U, Kobert N, Schaerer L, Hemmi S and Dummer R. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 2008; 68(3):650-656.
42. Tulchinsky E, Pringle JH, Caramel J and Ansieau S. Plasticity of melanoma and EMT-TF reprogramming. Oncotarget. 2014; 5(1):1-2.
43. Hoek KS and Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment cell & melanoma research. 2010; 23(6):746-759.
44. Sargiannidou I, Zhou J and Tuszynski GP. The role of thrombospondin-1 in tumor progression. Exp Biol Med (Maywood). 2001; 226(8):726-733.
45. Taraboletti G, Rusnati M, Ragona L and Colombo G. Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget. 2010; 1(7):662-673.
46. Lindner DJ, Wu Y, Haney R, Jacobs BS, Fruehauf JP, Tuthill R and Borden EC. Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis. Matrix Biol. 2013; 32(2):123-132.
47. Baker LH, Rowinsky EK, Mendelson D, Humerickhouse RA, Knight RA, Qian J, Carr RA, Gordon GB and Demetri GD. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol. 2008; 26(34):5583-5588.
48. Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J and Creagan ET. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007; 30(3):303-309.
49. Almendros I, Montserrat JM, Torres M, Dalmases M, Cabanas ML, Campos-Rodriguez F, Navajas D and Farre R. Intermittent hypoxia increases melanoma metastasis to the lung in a mouse model of sleep apnea. Respir Physiol Neurobiol. 2013; 186(3):303-307.
50. Feige E, Yokoyama S, Levy C, Khaled M, Igras V, Lin RJ, Lee S, Widlund HR, Granter SR, Kung AL and Fisher DE. Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(43):E924-933.
51. Liu S, Kumar SM, Martin JS, Yang R and Xu X. Snail1 mediates hypoxia-induced melanoma progression. Am J Pathol. 2011; 179(6):3020-3031.
52. Widmer DS, Hoek KS, Cheng PF, Eichhoff OM, Biedermann T, Raaijmakers MI, Hemmi S, Dummer R and Levesque MP. Hypoxia contributes to melanoma heterogeneity by triggering HIF1alpha-dependent phenotype switching. J Invest Dermatol. 2013; 133(10):2436-2443.
53. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM and Postovit LM. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer. 2007; 7(4):246-255.
54. Kulesa PM, Kasemeier-Kulesa JC, Teddy JM, Margaryan NV, Seftor EA, Seftor RE and Hendrix MJ. Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. Proc Natl Acad Sci U S A. 2006; 103(10):3752-3757.
55. Schriek G, Oppitz M, Busch C, Just L and Drews U. Human SK-Mel 28 melanoma cells resume neural crest cell migration after transplantation into the chick embryo. Melanoma Res. 2005; 15(4):225-234.
56. Tanaka K, Sonoo H, Kurebayashi J, Nomura T, Ohkubo S, Yamamoto Y and Yamamoto S. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma. Clin Cancer Res. 2002; 8(5):1125-1131.
57. Duquette M, Sadow PM, Lawler J and Nucera C. Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment. Front Endocrinol (Lausanne). 2013; 4:189.
58. Firlej V, Mathieu JR, Gilbert C, Lemonnier L, Nakhle J, Gallou-Kabani C, Guarmit B, Morin A, Prevarskaya N, Delongchamps NB and Cabon F. Thrombospondin-1 triggers cell migration and development of advanced prostate tumors. Cancer Res. 2011; 71(24):7649-7658.
59. Radziwon-Balicka A, Santos-Martinez MJ, Corbalan JJ, O'Sullivan S, Treumann A, Gilmer JF, Radomski MW and Medina C. Mechanisms of platelet-stimulated colon cancer invasion: role of clusterin and thrombospondin 1 in regulation of the P38MAPK-MMP-9 pathway. Carcinogenesis. 2014; 35(2):324-332.
60. Wang TN, Qian X, Granick MS, Solomon MP, Rothman VL, Berger 'Tuszynski GP. Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res. 1996; 63(1):39-43.
61. Yee KO, Connolly CM, Duquette M, Kazerounian S, Washington R and Lawler J. The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res Treat. 2009; 114(1):85-96.
62. Lin XD, Chen SQ, Qi YL, Zhu JW, Tang Y and Lin JY. Overexpression of thrombospondin-1 in stromal myofibroblasts is associated with tumor growth and nodal metastasis in gastric carcinoma. J Surg Oncol. 2012; 106(1):94-100.
63. Uchida H, Kuroki M, Shitama T, Hayashi H and Kuroki M. Activation of TGF-beta1 through up-regulation of TSP-1 by retinoic acid in retinal pigment epithelial cells. Curr Eye Res. 2008; 33(2):199-203.
64. Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A and Smyth GK. A comparison of background correction methods for two-colour microarrays. Bioinformatics. 2007; 23(20):2700-2707.
65. Breitling R, Armengaud P, Amtmann A and Herzyk P. Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS letters. 2004; 573(1-3):83-92.
66. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(43):15545-15550.
67. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4(2):249-264.